Pfizer To Provide New Zealand With 60,000 Treatment Courses Of Investigational Oral Antiviral Candidate

Pfizer New Zealand announced today an agreement with the New Zealand Government to supply 60,000 treatment courses of its investigational COVID-19 oral antiviral candidate, PF-07321332; ritonavir, subject to regulatory approval from Medsafe. If approved ...